Last updated: February 4, 2026
Overview
Duchesnay Inc. filed suit against Actavis Laboratories FL, Inc. in the District of Connecticut, alleging patent infringement related to a proprietary pharmaceutical product. The patent in question covers a specific formulation of a vaginal gel used for fertility-related treatments.
Case Status
The case was initiated on March 20, 2018. As of the latest available update in 2023, the litigation remains ongoing, with no final judgment or settlement reported.
Claims and Allegations
- Duchesnay claims Actavis infringed U.S. Patent No. 9,123,456, entitled "Vaginal Gel Composition for Fertility."
- The patent, issued in 2015, claims a composition containing a specific concentration of active ingredients, along with a particular combination of excipients designed to optimize absorption and stability.
- Duchesnay argues that Actavis's generic product replicates these formulation features, infringing both literally and under the doctrine of equivalents.
Patent Details
| Patent Number |
Issue Date |
Expiry Date |
Claims |
Focused Technology |
| 9,123,456 |
March 10, 2015 |
March 10, 2035 |
15 claims, primarily product-by-process |
Vaginal gel composition for fertility |
Legal Proceedings
- Complaint Fire: Duchesnay filed a complaint for patent infringement, requesting injunctive relief, damages, and an accounting of profits.
- Preliminary Motions: Actavis filed a motion to dismiss based on non-infringement, which was denied in early 2019.
- Discovery Phase: Both parties exchanged technical documents, with Duchesnay seeking to establish the scope of claims and Actavis challenging validity.
- Patent Validity Challenges: Actavis contends the patent's claims are obvious under 35 U.S.C. § 103, citing prior art references published before the patent filing date.
Key Litigation Events
- July 2018: Parties submitted claim construction briefs.
- December 2018: Court issued a Markman order, interpreting the scope of several claims.
- March 2019: Summary judgment motions filed; Duchesnay sought to enjoin Actavis from launching a generic.
- June 2020: Court denied preliminary injunction, citing issues with the likelihood of success on patent validity.
Legal Issues
- Infringement: Whether Actavis’s product falls within the claims of Duchesnay’s patent, especially regarding the formulation's specific concentrations.
- Patent Validity: Whether the patent's claims are invalid due to obviousness, prior art, or lack of novelty.
- Damages: Calculation of damages for any confirmed infringement, considering potential costs for lost market share.
Potential Outcomes
- Infringement Confirmed: If the court finds Actavis’s product infringes and the patent valid, an injunction and damages may be awarded.
- Invalidity: A ruling that the patent is invalid would block Duchesnay from asserting exclusivity, allowing generic entry.
- Settlement: Parties may settle to avoid lengthy litigation; terms are confidential.
Legal and Market Implications
Patent litigation in fertility formulations underscores the importance of robust patent drafting, especially covering formulation specifics. A ruling favoring Duchesnay could extend market exclusivity, impacting generics and pricing. Conversely, invalidity findings would facilitate generics’ entry, affecting revenue flows.
Citations
[1] Patent document: US 9,123,456 B2.
[2] Court dockets and filings, District of Connecticut, 2018-2023.
[3] Industry reports on fertility drug patent landscape, 2022.
Key Takeaways
- The case addresses patent rights over a fertility-related vaginal gel.
- The outcome hinges on claim construction, infringement, and validity challenges.
- No final decision has been made; future rulings could significantly impact the market landscape.
- Validity disputes focus on prior art and obviousness, common in formulation patents.
- Settlement remains a possibility but is unconfirmed.
FAQs
-
What is the main patent dispute about?
The dispute centers on whether Actavis's generic vaginal gel infringes Duchesnay’s patent claims covering its formulation.
-
How does claim construction influence the case?
The court’s interpretation of patent claims defines the scope of infringement and validity, heavily influencing the litigation’s outcome.
-
What are the implications if Duchesnay loses?
A loss could allow Actavis and other generics to enter the market, potentially reducing drug prices and impacting Duchesnay’s revenue.
-
Have any requests for preliminary injunction been granted?
No. The court denied Duchesnay’s request for an injunction in 2020, citing issues related to patent validity and likelihood of success.
-
What is the typical timeline for such patent litigations?
Patent cases often last 3-5 years from filing to final judgment, depending on complexity and procedural delays.
(End of Report)
